LG Chem subsidiary files domestic marketing approval for Zemidapam ER 50/10/1000 mg targeting 2027 launch; no immediate financial impact
LG Chem's subsidiary LG Chem has filed a domestic marketing authorization application for Zemidapam ER tablets 50/10/1000 mg, a triple combination therapy for type 2 diabetes, with the Ministry of Food and Drug Safety.
The product contains gemigliptin, dapagliflozin, and metformin. Phase 3 trials demonstrated superior glycemic control vs placebo with a favorable safety profile.
The company aims to improve patient compliance and plans to launch the product in 2027.
This disclosure is a regulatory milestone without any capital change or dilution, limiting direct financial impact on the stock price.
[AI Summary]LG Chem's filing for a triple combo diabetes drug is a positive step in pipeline development, but final approval and commercialization remain uncertain. Near-term stock impact is limited; approval outcome and launch timing will be key value drivers.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (Application for Domestic Item Approval of Gemidapaem Seobangjeong)